Catrina, AI, Lampa, J, Ernestam, S, af Klint, E, Bratt, J, Klareskog, L et al.. Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford) 41: 484-489

Department of Rheumatology, Karolinska Hospital, Stockholm, Sweden.
Rheumatology (Impact Factor: 4.48). 06/2002; 41(5):484-9. DOI: 10.1093/rheumatology/41.5.484
Source: PubMed


Matrix metalloproteinases (MMPs) are cytokine-modulated enzymes that play an important role in the pathogenesis of rheumatoid arthritis (RA) by inducing bone resorption and cartilage destruction. This study evaluated the modulation of serum and synovial MMPs and their inhibitor, tissue inhibitor of matrix metalloproteinases (TIMP)-1, by therapy with soluble tumour necrosis factor (TNF) alpha receptor (etanercept).
Serum samples were collected from 60 RA patients at baseline and after 8 or 12 weeks of treatment. Paired synovial biopsies were obtained from 11 patients at two time points, before and after 8 weeks of treatment. We measured serum levels of MMP-1, MMP-3 and TIMP-1 by ELISA. Immunohistological analysis of synovial tissue was performed using monoclonal antibodies specific for MMP-1, MMP-3 and TIMP-1.
Etanercept therapy significantly down-regulated serum levels of MMP-3 and MMP-1 in parallel with the reduction in inflammatory parameters (C-reactive protein concentration and erythrocyte sedimentation rate) in RA patients. Baseline pretreatment serum levels of MMP-3 correlated with changes in clinical disease activity during therapy. No consistent changes in serum level of TIMP-1 were observed, while ratios of MMP-1 and MMP-3 to TIMP-1 were down-regulated following etanercept treatment. Immunohistochemical analyses revealed great interindividual variability, with generally a high level of expression of MMP and low expression of TIMP. No significant change in the pattern or number of positive cells occurred during therapy.
In RA patients, etanercept therapy down-regulates serum levels of MMP-3 and MMP-1 and the ratio between MMPs and TIMP-1. This may be an important mechanism for the prevention of future development of joint damage.

29 Reads
  • Source
    • "These also included several pain-related known genes, such as the voltage-dependent calcium channel subunit aplha2/delta1 (Cacna2d1) [23], the AMPA receptor interacting protein, GRIP1 [24,25], amongst others (Figure  1C). Interestingly, however, 421 genes showed reciprocal regulation upon exposure to GMCSF or GCSF (Figure  1B), e.g. the nociceptive modulatory chemokine (C-C motif) ligand (Ccl5) [26] and the matrix metalloprotease 3 (MMP3) [27,28] were significantly upregulated after GMCSF exposure, but downregulated upon exposure to GCSF (Figure  1C). In general, genes encoding nociceptive modulating pronociceptive chemokines and cytokines appeared more strongly regulated by GMCSF signaling than by GCSF signaling in DRG neurons (some examples in Figure  1C). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer-associated pain is a major cause of poor quality of life in cancer patients and is frequently resistant to conventional therapy. Recent studies indicate that some hematopoietic growth factors, namely granulocyte macrophage colony stimulating factor (GMCSF) and granulocyte colony stimulating factor (GCSF), are abundantly released in the tumor microenvironment and play a key role in regulating tumor-nerve interactions and tumor-associated pain by activating receptors on dorsal root ganglion (DRG) neurons. Moreover, these hematopoietic factors have been highly implicated in postsurgical pain, inflammatory pain and osteoarthritic pain. However, the molecular mechanisms via which G-/GMCSF bring about nociceptive sensitization and elicit pain are not known. In order to elucidate G-/GMCSF mediated transcriptional changes in the sensory neurons, we performed a comprehensive, genome-wide analysis of changes in the transcriptome of DRG neurons brought about by exposure to GMCSF or GCSF. We present complete information on regulated genes and validated profiling analyses and report novel regulatory networks and interaction maps revealed by detailed bioinformatics analyses. Amongst these, we validate calpain 2, matrix metalloproteinase 9 (MMP9) and a RhoGTPase Rac1 as well as Tumor necrosis factor alpha (TNFalpha) as transcriptional targets of G-/GMCSF and demonstrate the importance of MMP9 and Rac1 in GMCSF-induced nociceptor sensitization. With integrative approach of bioinformatics, in vivo pharmacology and behavioral analyses, our results not only indicate that transcriptional control by G-/GMCSF signaling regulates a variety of established pain modulators, but also uncover a large number of novel targets, paving the way for translational analyses in the context of pain disorders.
    Molecular Pain 09/2013; 9(1):48. DOI:10.1186/1744-8069-9-48 · 3.65 Impact Factor
  • Source
    • "MMP-3 levels are significantly increased both in serum and synovial fluid in RA patients (Zucker et al., 1994; Ishiguro et al., 1996). Serum MMP-3 levels are decreased by anti-TNF-α therapy in RA, suggesting that TNF-α may induce MMP-3 expression (Ca-trina et al., 2002). It has also been shown that MMP-3 levels in synovial fluid (SF) are significantly related with the concentration of soluble FasL (sFasL) in SF of patients with RA, which indicates that MMP-3 may regulate the shedding of FasL (Matsuno et al., 2001). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Matrix metalloproteinases (MMPs) are a subfamily of zinc-dependent proteases that are responsible for degradation and remodeling of extracellular matrix proteins. The activity of MMPs is tightly regulated at several levels including cleavage of prodomain, allosteric activation, compartmentalization and complex formation with tissue inhibitor of metalloproteinases (TIMPs). In the central nervous system (CNS), MMPs play a wide variety of roles ranging from brain development, synaptic plasticity and repair after injury to the pathogenesis of various brain disorders. Following general discussion on the domain structure and the regulation of activity of MMPs, we emphasize their implication in various brain disorder conditions such as Alzheimer's disease, multiple sclerosis, ischemia/reperfusion and Parkinson's disease. We further highlight accumulating evidence that MMPs might be the culprit in Parkinson's disease (PD). Among them, MMP-3 appears to be involved in a range of pathogenesis processes in PD including neuroinflammation, apoptosis and degradation of α-synuclein and DJ-1. MMP inhibitors could represent potential novel therapeutic strategies for treatments of neurodegenerative diseases.
    Biomolecules and Therapeutics 03/2012; 20(2):133-143. DOI:10.4062/biomolther.2012.20.2.133 · 1.73 Impact Factor
  • Source
    • "TNF-alpha inhibition reduces the cellularity of inflamed tissues, inhibits expression of proinflammatory cytokines including IL-1β, Il-6, Il-8 and GM-CSF, growth factors VEGF and chemokines such as MCP-1, all of which contribute to atherosclerosis. Inhibition also reduces TNFalpha induced expression of matrix metalloproteinases (MMPs), MMP-1 and MMP-3 (Catrina et al., 2002). This reduction in MMPs has the potential to reduce collagen degradation and increase the stability of atherosclerotic lesions (Aikawa et al., 2001). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular disease is the largest cause of morbidity and premature mortality and its major underlying pathology is atherosclerosis. Atherosclerosis commences with the deposition of lipids in the artery wall due to trapping by proteoglycans. Trapped lipoproteins are chemically and enzymatically modified to yield pro-inflammatory species that induce adhesion molecule expression on endothelial cells leading to the recruitment of multiple species of immune cells and a chronic inflammatory response. Ongoing remodelling of the vessel and later morphological changes generate "vulnerable" plaques, the acute rupture of which generates the clinical event. The major medical therapies are anti-hypertensives and lipid lowering agents. Although these therapies are amongst the most efficacious in cardiovascular medicine, in optimised well-controlled clinical trials the maximum effect is limited to an approximately 30% reduction in cardiovascular events. Hence, a huge burden of disease remains refractory to current therapies and atherosclerosis and its sequelae persist as a therapeutic target of immense importance. Potential therapeutic targets include the proteoglycan: lipoprotein interaction in the vessel wall, circulating and vessel wall associated atherogenic lipid species and the immune system. Anti-inflammatory therapies include specific cytokine antagonists and cytokine neutralizing antibodies, specific immune cell depleting antibodies and cell therapies using antigen specific regulatory T-cells and regulatory B-cells. In this review, we describe the process of atherosclerosis as it involves the role of chronic inflammation in the development and progression of atherosclerotic plaques and then the manner in which some of these inflammatory processes represent therapeutic targets.
    Pharmacology [?] Therapeutics 04/2011; 131(3):255-68. DOI:10.1016/j.pharmthera.2011.04.001 · 9.72 Impact Factor
Show more

Full-text (2 Sources)

29 Reads
Available from
Nov 7, 2014